Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

Monica D. Levine; David M. O'Malley; Paulina J. Haight; Leigha Senter; Vincent Wagner; Kristin L. Bixel; David E. Cohn; Larry J. Copeland; Casey M. Cosgrove; Eric M. McLaughlin; Floor J. Backes

doi:10.1016/j.gore.2023.101173

Back

Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

Journal article

Open access

Peer reviewed

Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?

Monica D. Levine, David M. O'Malley, Paulina J. Haight, Leigha Senter, Vincent Wagner, Kristin L. Bixel, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Eric M. McLaughlin, …

Gynecologic oncology reports, Vol.46, pp.101173-101173

04/01/2023

DOI: 10.1016/j.gore.2023.101173

PMCID: PMC10111944

PMID: 37082521

Files and links (1)

url

https://doi.org/10.1016/j.gore.2023.101173View

Published (Version of record) Open Access

Abstract

• Despite a high rate of complete surgical staging and six cycles of adjuvant chemotherapy, the risk of recurrence was 37%. • Recurrence rate was higher for homologous recombination deficiency (HRD, 70%) cases compared to proficient/unknown cases. • Shorter recurrence-free survival was seen among HRD cases compared to proficient/unknown cases. • Only 25% of HRD cases were due to germline BRCA mutations, with the remaining 75% identified as HRD by somatic testing. • Studying the role of PARP inhibitors in patients with early stage HRD ovarian cancer to improve outcomes is warranted.

Research Report

Details

Title: Subtitle: Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Creators: Monica D. Levine - The Ohio State University
David M. O'Malley - The Ohio State University
Paulina J. Haight - The Ohio State University
Leigha Senter - The Ohio State University
Vincent Wagner - The Ohio State University
Kristin L. Bixel - The Ohio State University
David E. Cohn - The Ohio State University
Larry J. Copeland - The Ohio State University
Casey M. Cosgrove - The Ohio State University
Eric M. McLaughlin - The Ohio State University
Floor J. Backes - The Ohio State University
Resource Type: Journal article
Publication Details: Gynecologic oncology reports, Vol.46, pp.101173-101173
DOI: 10.1016/j.gore.2023.101173
PMID: 37082521
PMCID: PMC10111944
NLM abbreviation: Gynecol Oncol Rep
ISSN: 2352-5789
eISSN: 2352-5789
Publisher: Elsevier
Grant note: DOI: 10.13039/100013699, name: The Ohio State University OSUCCC – James
Language: English
Date published: 04/01/2023
Academic Unit: Obstetrics and Gynecology
Record Identifier: 9984460334802771

Metrics

4 Record Views

5 Times Cited - Web of Science